Jennison Associates LLC Takes Position in Metsera Inc. (NASDAQ:MTSR)

Jennison Associates LLC bought a new position in Metsera Inc. (NASDAQ:MTSR - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 355,567 shares of the company's stock, valued at approximately $9,679,000. Jennison Associates LLC owned approximately 0.34% of Metsera at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. New York State Common Retirement Fund purchased a new stake in shares of Metsera during the first quarter valued at $131,000. Bank of New York Mellon Corp purchased a new stake in shares of Metsera during the 1st quarter valued at about $884,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Metsera in the first quarter worth approximately $13,111,000. Finally, Alphabet Inc. bought a new stake in shares of Metsera in the first quarter worth approximately $135,059,000.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MTSR. Guggenheim raised their target price on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Wells Fargo & Company began coverage on Metsera in a research note on Friday, June 20th. They issued an "overweight" rating and a $65.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $55.00.

Metsera Trading Down 0.9%

Shares of MTSR traded down $0.34 on Thursday, reaching $39.65. The company's stock had a trading volume of 752,750 shares, compared to its average volume of 748,635. The company's 50 day moving average price is $31.62. Metsera Inc. has a 12-month low of $12.30 and a 12-month high of $47.40.

Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.